Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Microarray Immunoassay Improves Accuracy and Speed of Celiac Disease Diagnosis

By LabMedica International staff writers
Posted on 05 Sep 2024

Celiac disease is a chronic autoimmune disorder affecting one in every hundred people globally, primarily impacting the small intestine and often presenting with a range of multiorgan symptoms. More...

The disease is characterized by an inappropriate immune response to gluten in individuals who are genetically predisposed, which leads to autoantibody production and damage to the small bowel. The standard diagnostic process includes serological tests for specific autoantibodies, supplemented by other clinical, laboratory, imaging, genetic, and histopathological assessments. Now, a multiplexed microarray immunoassay designed to improve the accuracy and speed of diagnosing celiac disease can help better the lives of affected patients.

AliveDx’s (Eysins, Switzerland) multiplexed MosaiQ AiPlex CD microarray immunoassay provides a novel and efficient solution to streamline the diagnosis process and alleviate the unnecessary burden associated with celiac disease testing. Clinical guidelines suggest screening for IgA autoantibodies against tissue Transglutaminase (anti-tTG IgA) and Deamidated Gliadin Peptides (anti-DGP IgA). Considering the prevalence of selective IgA deficiency among some individuals with celiac disease, assessments of total IgA levels to accompany autoantibody tests are recommended. In instances of IgA deficiency, it is advised to check for pertinent IgG autoantibodies (e.g., anti-tTG IgG, anti-DPG IgG).

The MosaiQ AiPlex CD immunoassay incorporates the most clinically significant autoantibodies, namely tTG IgA, DGP IgA, tTG IgG, and DGP IgG, along with total IgA antibodies detection, offering comprehensive diagnostic insights from a single sample and blood draw. This facilitates laboratories in automating and simplifying the diagnostic process for celiac disease. Following a diagnosis, immediate adoption of a Gluten-Free Diet (GFD) is beneficial for patients, not only in alleviating gastrointestinal symptoms but also in preventing serious long-term health issues. AliveDx’s MosaiQ AiPlex CD microarray immunoassay has been awarded the IVDR-CE mark certification, confirming its safety, efficacy, and readiness for broad clinical application in regions accepting the CE mark.

"We are thrilled to obtain the CE mark for our MosaiQ AiPlex CD microarray," said Manuel O. Mendez, CEO of AliveDx. "The MosaiQ fast portfolio expansion marks our fourth microarray CE mark approval in the last 12 months reflecting our dedication to rapidly advance diagnostic technologies and our commitment to support the millions of individuals affected by autoimmune diseases. Early and accurate diagnosis is crucial for managing this condition. Our innovative MosaiQ microarray solutions represent a significant advancement to partner with laboratorians and clinicians to reduce healthcare costs and improve patient outcomes and quality of life."

Related Links:
AliveDx


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Portable Electronic Pipette
Mini 96
New
Pipette
Accumax Smart Series
New
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.